

PATENT APPLICATIONRECEIVED
CENTRAL FAX CENTER

NOV 01 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Paul O. Sheppard et al.

Serial No.: 10/607,706

Group Art Unit No.: 1647

Filed: June 27, 2003

Examiner: Romeo, David

For: TML POLYNUCLEOTIDES

Docket No.: 97-04D3
(A-933-E)INFORMATION DISCLOSURE STATEMENTMail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form

Applicants make no determination of relevancy with respect to the reference(s) submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the reference(s).

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/404,417 (now U.S. Patent No. 6,627,729), filed September 23, 1999. The present application is a divisional of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).]

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

CERTIFICATE OF FACSIMILE TRANSMISSION


I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

November 1, 2006
DateKathleen P. Pharis
Kathleen P. Pharis

PATENT APPLICATION

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Christine M. Bellas
Attorney/Agent for Applicant(s)
Registration No.: 34,122
Phone: (206) 265-8294
Date: November 1, 2006

Please send all future correspondence to:

Amgen Inc.
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105
(206) 265-7000

hk011902 11/1/06

Sheet 1 Of 2

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	97-04D3 (A-933-E)	Serial No.	10/607,706
	Applicant			
	Paul O. Sheppard et al.			
Filing Date		June 27, 2003	Group	1647

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,006,469 A	4/1991	Adelman et al.	435	240.1	
	A2	5,470,830 A	11/1995	Macielag et al.	514	13	
	A3	6,380,158 B1	4/2002	Sheppard	514	12	
	A4						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	WO 98/42840	10/1998	PCT				
	B2							

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C1	U.S. Application No. 09/608,810, filed June 30, 2000.
C2	Pearson et al., <i>Gastrointestinal Hormones in Medicine</i> 22:753-774, 1993.
C3	Daikh et al., <i>DNA</i> 8:615-621, 1989.
C4	INC2207941, LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals Inc., 1996.
C5	INC1328219, LIFESEQ™ Clone Information Results, Incyte Pharmaceuticals Inc., 1996.
C6	INC2209486, LIFESEQ™, Clone Information Results, Incyte Pharmaceuticals Inc., 1996.
C7	INC1851527, LIFESEQ™, Clone Information Results, Incyte Pharmaceuticals Inc., 1996.
C8	INC891710, LIFESEQ™, Clone Information Results, Incyte Pharmaceuticals Inc., 1996.
C9	INC1329031, LIFESEQ™, Clone Information Results, Incyte Pharmaceuticals Inc., 1996.
C10	Clone 1329031, LIFESEQ™, Electronic Northern Results, Incyte Pharmaceuticals Inc., 1996.
C11	PANCNOT07, LIFESEQ™, Library Information Results, Incyte Pharmaceuticals Inc., 1996.
C12	LUNGFET03, LIFESEQ™, Library Information Results, Incyte Pharmaceuticals Inc., 1996.
C13	STOMTUT01, LIFESEQ™, Library Information Results, Incyte Pharmaceuticals Inc., 1996.
C14	SINTFET03, LIFESEQ™, Library Information Results, Incyte Pharmaceuticals Inc., 1996.
C15	Strausberg, Accession No. AA530994, Cancer Genome Anatomy Project, 1997.
C16	INC3663175, LIFESEQ™, Clone Information Results, Incyte Pharmaceuticals Inc., 1997.
C17	INC3666305, LIFESEQ™, Clone Information Results, Incyte Pharmaceuticals Inc., 1997.
C18	INC3605169, LIFESEQ™, Clone Information Results, Incyte Pharmaceuticals Inc., 1997.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

